The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | CAR T-cell–driven induction of iNOS in TAMs promotes CAR T-cell resistance in B-cell lymphoma
Marco Davila, MD, PhD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, discusses research identifying tumor-associated macrophages (TAMs) as a key driver of resistance to CD19 CAR T-cell therapy in lymphoma. Preclinical models demonstrated TAMs can impair or kill CAR T-cells through metabolic and proteomic mechanisms, highlighting inducible nitric oxide synthase (iNOS) as a potential therapeutic target to improve durable responses. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
